Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
C 52.29 -0.80% -0.42
AZN closed down 0.75 percent on Thursday, April 22, 2021, on 87 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Up Up
Historical AZN trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish -0.74%
Slingshot Bullish Bullish Swing Setup -0.74%
Upper Bollinger Band Walk Strength -0.74%
Overbought Stochastic Strength -0.74%
Upper Bollinger Band Touch Strength -0.74%
Crossed Above 200 DMA Bullish -1.49%
Upper Bollinger Band Walk Strength -1.49%
Above Upper BB Strength -1.49%
Gapped Up Strength -1.49%
Overbought Stochastic Strength -1.49%
Older End-of-Day Signals for AZN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 1 hour ago
Down 1% about 21 hours ago
Fell Below Previous Day's Low about 22 hours ago
60 Minute Opening Range Breakdown about 22 hours ago
Fell Below 200 DMA about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Astrazeneca PLC Description

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Cancer Acid Drugs Antibodies Inflammation Monoclonal Antibodies Gastrointestinal Breast Cancer Neuroscience Hypertension Infection Inflammatory Disease Inflammatory Diseases Coronavirus Schizophrenia Kidney Disease Psychoactive Drugs Heart Failure Asthma Pulmonary Disease Cholesterol Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Major Depressive Disorder Anemia Depressive Disorder Renal Disease Respiratory Disease End Stage Renal Disease Primary Care Stage Renal Disease Autoimmune And Inflammatory Diseases Autoimmune And Inflammatory Disease Pulmonology Angina Bipolar Disorder Chronic Condition Chronic Obstructive Pulmonary Diseases Nanomedicine Major Depressive Disorders Respiratory Infection Bipolar Disorders Inflammation Diseases Linaclotide

Is AZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 64.94
52 Week Low 46.48
Average Volume 10,698,211
200-Day Moving Average 52.77
50-Day Moving Average 49.79
20-Day Moving Average 50.34
10-Day Moving Average 50.97
Average True Range 0.88
ADX 14.85
+DI 40.29
-DI 21.25
Chandelier Exit (Long, 3 ATRs ) 50.53
Chandelier Exit (Short, 3 ATRs ) 50.90
Upper Bollinger Band 52.78
Lower Bollinger Band 47.89
Percent B (%b) 0.99
BandWidth 9.71
MACD Line 0.71
MACD Signal Line 0.33
MACD Histogram 0.3765
Fundamentals Value
Market Cap 138.34 Billion
Num Shares 2.62 Billion
EPS 0.95
Price-to-Earnings (P/E) Ratio 55.48
Price-to-Sales 5.36
Price-to-Book 11.36
PEG Ratio 1.22
Dividend 1.40
Dividend Yield 2.66%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.72
Resistance 3 (R3) 53.73 53.42 53.55
Resistance 2 (R2) 53.42 53.16 53.41 53.49
Resistance 1 (R1) 53.06 53.00 52.91 53.05 53.44
Pivot Point 52.75 52.75 52.67 52.74 52.75
Support 1 (S1) 52.39 52.49 52.24 52.38 51.98
Support 2 (S2) 52.08 52.33 52.07 51.93
Support 3 (S3) 51.72 52.08 51.87
Support 4 (S4) 51.71